“…However, our data support the assumption that in cases in whom the primary tumor has been definitively treated (i.e., eyes with no evidence of tumor growth at the time of GDD placement), the risk to the patient following invasive glaucoma surgery is not greater than clinical risk factors, namely tumor size and molecular prognostic profile, would suggest. Treatment of glaucoma in eyes with intraocular tumors, which is often caused by multiple mechanisms (incidence rate of 15.3% [Kim et al, manuscript under revision]) [1, 3, 28], may be challenging, and medical therapy, laser trabeculoplasty, and cyclophotocoagulation may not lead to adequate IOP control [11, 29, 30]. Cyclophotocoagulation is a treatment that may result in eventual phthisis if repeated more than once; therefore, offering cyclophotocoagulation may be minimally better than enucleation for ocular preservation [31].…”